Skip to main content
Universal Drugstore logo

Why pay full price for medications?

See Prices Now

Evorel Conti vs FemSeven: A Complete HRT Patch Comparison Guide

In This Article

Understanding HRT Patches: Evorel Conti vs FemSeven

Hormone replacement therapy (HRT) patches offer women a convenient way to manage menopause symptoms through the skin. Two popular options are Evorel Conti and FemSeven patches, both designed to deliver estrogen and progestogen hormones directly into the bloodstream.

Shop Medications

Evorel Conti patches contain estradiol hemihydrate combined with norethisterone acetate, providing continuous combined hormone therapy for postmenopausal women who are at least one year past their last menstrual period. FemSeven patches offer both continuous (FemSeven Conti) and sequential (FemSeven Sequi) hormone delivery options for women experiencing estrogen deficiency symptoms.

The main difference between these HRT patches lies in their dosing schedules, hormone combinations, and application frequency. Understanding these differences helps women and their healthcare providers choose the most suitable option for managing menopause symptoms.

How Evorel Conti Patches Work

Evorel Conti patches deliver a steady dose of two hormones through the skin: estradiol (a form of estrogen) and norethisterone acetate (a synthetic progestogen). This combination provides continuous hormone therapy without the monthly bleeding that often occurs with sequential HRT regimens.

Why Pay Full Price?

Search our full medication catalogue and save up to 80% - no insurance needed.

See Prices Now

The patches are applied twice weekly, typically on the same two days each week. Each patch delivers hormones for approximately 3.5 days before needing replacement. The continuous delivery system helps maintain steady hormone levels in the bloodstream, which may reduce symptom fluctuations between doses.

Women using Evorel Conti should expect minimal or no monthly bleeding, as the continuous progestogen component prevents the uterine lining from building up significantly. This makes Evorel Conti particularly suitable for women who want to avoid regular menstrual periods while receiving hormone therapy.

FemSeven Patch Options and Mechanisms

FemSeven offers two distinct hormone therapy approaches through different patch formulations. FemSeven Conti provides continuous combined hormone therapy similar to Evorel Conti, while FemSeven Sequi follows a sequential pattern that mimics natural menstrual cycles.

The key advantage of FemSeven patches is their once-weekly application schedule. Each patch provides seven days of hormone delivery, potentially improving convenience and adherence compared to twice-weekly applications. This extended wear time may appeal to women with busy lifestyles or those who prefer less frequent medication management.

FemSeven Sequi uses different patches during the monthly cycle: estrogen-only patches for part of the month, followed by combined estrogen-progestogen patches. This sequential approach typically results in monthly withdrawal bleeding similar to natural menstruation, which some women prefer for psychological comfort or bleeding pattern predictability.

Dosing and Application Differences

The most practical difference between Evorel Conti patches vs FemSeven lies in their application schedules. Evorel Conti requires twice-weekly patch changes, typically applied on the same two days each week, such as Sunday and Thursday. Each patch should be worn for approximately 3.5 days before replacement.

FemSeven patches need changing only once per week, with each patch designed to deliver consistent hormone levels for seven full days. Many women find this weekly schedule easier to remember and more convenient for travel or busy periods.

Both patch systems should be applied to clean, dry, hairless skin on the lower body, typically the buttocks or lower abdomen. The application site should be rotated with each new patch to prevent skin irritation. Neither type should be applied to the breasts or waistline where clothing might rub against the patch.

Effectiveness for Menopause Symptoms

Both Evorel Conti and FemSeven patches effectively treat common menopause symptoms including hot flashes, night sweats, mood changes, and vaginal dryness. The transdermal delivery method allows hormones to enter the bloodstream directly, bypassing the digestive system and potentially reducing some side effects compared to oral hormone therapy.

Clinical studies show that continuous combined HRT patches like both Evorel Conti and FemSeven Conti effectively eliminate monthly bleeding in most women while controlling vasomotor symptoms. The steady hormone delivery through patch technology helps maintain consistent symptom relief throughout the wearing period.

For women preferring regular monthly bleeding, FemSeven Sequi provides effective symptom control while maintaining a more natural bleeding pattern. This sequential approach may be preferred by women who find complete cessation of periods psychologically uncomfortable or who want to maintain some semblance of their natural cycle.

Common Side Effects Comparison

Common Side Effects

Both patch systems share similar common side effects due to their hormone content. Application site reactions occur in approximately 11.7% of Evorel Conti users, making it the most frequent side effect. These reactions typically include redness, itching, or mild skin irritation at the patch site.

Other common side effects include headache (occurring in approximately 8.2% of users), menstrual disorders (7.1%), and breast pain or tenderness (5.1%). FemSeven patches report similar side effect patterns, with application site reactions affecting more than 10% of users, and breast tenderness, headache, and digestive issues occurring in 1-10% of women.

Serious but Rare Side Effects

Both Evorel Conti and FemSeven carry similar risks associated with combined hormone replacement therapy. The risk of venous thromboembolism (blood clots) increases by 1.3 to 3-fold with HRT use, with a higher incidence typically occurring in the first year of treatment.

Breast cancer risk increases with extended use of combination estrogen-progestogen HRT, becoming apparent after 3 to 5 years of continuous use. Ovarian cancer risk also increases, with studies showing approximately one extra case per 2000 users over five years of treatment.

Who Should Consider Each Option

Evorel Conti patches may be ideal for women who prefer twice-weekly medication management and want to completely stop monthly bleeding. The shorter wearing period might suit women with sensitive skin who experience irritation with longer patch wear times. Women who like having more control over their hormone therapy schedule may prefer the flexibility of twice-weekly applications.

FemSeven patches work well for women prioritizing convenience and simplicity in their HRT regimen. The once-weekly application schedule appeals to busy professionals, frequent travelers, or those who prefer minimal medication management. Women who want options for both continuous and sequential therapy might appreciate having both FemSeven Conti and FemSeven Sequi available within the same product line.

Both options require consultation with healthcare providers to determine suitability based on individual health history, symptom severity, and personal preferences. Factors like previous hormone therapy experience, bleeding preferences, and lifestyle considerations all influence the optimal choice.

Long-Term Safety Considerations

Both Evorel Conti and FemSeven patches carry similar long-term safety profiles as combination hormone replacement therapies. Extended use of combined HRT is associated with increased risks of breast cancer, with the risk level depending on dose, duration, and individual patient factors.

Recent evidence suggests that cardiovascular risks may be lower than previously thought, particularly for women who begin HRT within 10 years of menopause. Studies show no increase in cardiovascular events, cardiovascular mortality, or all-cause mortality in women who initiated HRT more than 10 years after menopause.

Regular monitoring and risk assessment remain essential for all women using combination HRT patches. Healthcare providers typically recommend annual reviews to assess ongoing benefits versus risks, adjust dosing if needed, and monitor for any concerning symptoms or changes in health status.

Making the Right Choice for Your Needs

Choosing between Evorel Conti patches vs FemSeven depends on individual preferences, lifestyle factors, and medical considerations. Women should discuss their symptom severity, bleeding preferences, medication management capabilities, and risk factors with their healthcare providers.

Key decision factors include application frequency preferences (twice weekly versus once weekly), desired bleeding patterns (continuous versus sequential options), skin sensitivity to adhesives, and overall convenience requirements. Some women may need to try both options to determine which works better for their individual needs and tolerance.

The effectiveness of both patch systems in controlling menopause symptoms is generally comparable, making personal preference and practical considerations important factors in the decision-making process. Regular follow-up appointments help ensure the chosen HRT option continues to meet changing needs while maintaining appropriate safety monitoring.

References

Related Conditions